Lorenzo Cavagna
Lorenzo Cavagna is an expert in Rheumatology at Policlinico San Matteo Fondazione (Italy). As of September 2026, ScienceLeadR ranks Lorenzo Cavagna in the top 1% of experts worldwide for Myositis. Lorenzo Cavagna has authored 318 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 3 of them ongoing. SLR score: 1,025 (community average: 125). How the SLR is computed.
LeadR Profile
Rheumatology
Subspecialties: Internal Medicine - Public Health - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2001 - 2026
Number : 318
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Immune-mediated necrotizing myopathies: clinico-serological features and treatment outcomes of a large Italian cohort of patients. PMID 42671644 — muscular diseases, neurosurgery, therapeutics, neurology | J Neurol | 2026 | 0 |
| Mental- and physical-health comorbidity are strongly associated in idiopathic inflammatory myopathies: a multinational cross-sectional e-survey. PMID 42667389 — muscular diseases, rheumatology, comorbidity, pain, neoplasms, fatigue, myositis, multimorbidity, morbidity | Rheumatol Int | 2026 | 0 |
| Targeting type I interferon in lupus autoimmune haemolytic anaemia: first report with anifrolumab. PMID 42508961 — laboratories, anemia, anemia, hemolytic, lupus erythematosus, systemic, interferon type i, hemolysis, therapeutics, anemia, hemolytic, autoimmune, coombs test | Lupus Sci Med | 2026 | 0 |
| The landscape of serum autoantibodies in lupus nephritis. PMID 42409299 — proteinuria, autoantibodies, serum, antibodies, lupus nephritis, biomarkers, signs and symptoms, histones, nephritis, autoimmunity | Autoimmun Rev | 2026 | 0 |
| Sex differences in idiopathic inflammatory myopathies: insights from a large multicentre observational study. PMID 42154643 — muscular diseases, rheumatology, multiple chronic conditions, connective tissue diseases, myositis, sex characteristics, sex, sex differences | Clin Exp Rheumatol | 2026 | 0 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 2
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A study of the efficacy and safety of Belimumab in adults with interstitial lung disease associated with connective tissue disease 2024-513018-36-00 — lung, safety, connective tissue, connective tissue diseases, lung diseases, tissues, lung diseases, interstitial | Phase 3 | Recruiting | 2025 |
| A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis) 2023-504022-19-01 — dermatomyositis, muscular diseases, injections, safety, classification, myositis, polymyositis, therapeutics, injections, subcutaneous | Phase 3 | Not yet recruiting | 2024 |
| Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus Investigator Initiated Observational Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients NCT07215754 — quality of life, safety, incidence, pharmaceutical preparations, lupus erythematosus, systemic, drug-related side effects and adverse reactions, herpes zoster, therapeutics, steroids | N/A | Recruiting | 2023 |
LeadR Networks
Main global connection map